INDV241220C12500
- 0.50
- 0.000.00%
Indivior Newsroom
Indivior to Engage With Investors at Healthcare Conference
Indivior Shares Sublocade Trial Findings at CSAM Conference
Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs....
Indivior PLC Executes Strategic Share Repurchase
Indivior's Voting Rights Shift With Madison Avenue
US Manufacturing Index Rises To 43, Highest Since 2020
Indivior Extends Board Tenure Amidst Shareholder Changes
Deerfield's Strategic Stake Acquisition in Indivior
M&A Deals Roundup: Blackstone, BCE, CrowdStrike, Danone and More
Indivior Shareholder Oaktree Capital Calls for Board Refresh
Indivior Engages With Oaktree on Value Proposals
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
Indivior Jumps Amid Takeover Speculation
Indivior Boosts Shareholder Value With Repurchase Program
Indivior Boosts Liquidity With $400 Million Refinancing
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Raises Target Price to $16
Earnings Call: Indivior PLC Reports Strong Q3 Revenue Growth, Eyes Expansion
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript Summary
Indivior | 6-K: Report of foreign private issuer (related to financial reporting)
Earnings Preview: Indivior to Report Financial Results Pre-market on October 24